Literature DB >> 19186239

The surgical and systemic management of neuroendocrine tumors of the pancreas.

Gerard J Abood1, Aileen Go, Deepak Malhotra, Margo Shoup.   

Abstract

Neuroendocrine tumors of the pancreas comprise a class of rare tumors that can be associated with symptoms of hormone overproduction. Five distinct clinical endocrinopathies are associated with neuroendocrine tumors; however, most of these tumors remain asymptomatic and follow an indolent course. Complete surgical resection offers the only hope for cure, but understanding the basic biology of the tumors has advanced the medical management in metastatic disease. Surgical resection of hepatic metastases offers survival advantage and should be performed when feasible. Although hepatic artery embolization is currently the preferred mode of nonsurgical palliation for pain and hormonal symptoms, other modalities may play a role in metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19186239     DOI: 10.1016/j.suc.2008.10.001

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  13 in total

1.  Breast and lung metastasis from pancreatic neuroendocrine carcinoma.

Authors:  Shevonne Satahoo-Dawes; Joshua Palmer; Eddie W Manning; Joe Levi
Journal:  World J Radiol       Date:  2011-01-28

2.  Hypoglycaemia in a 94-year-old man without diabetes.

Authors:  Dustin James Mullens; Jay H Shubrook
Journal:  BMJ Case Rep       Date:  2014-05-20

3.  Surgical resection and multidisciplinary care for primary and metastatic pancreatic islet cell carcinomas.

Authors:  Shaun McKenzie; Wendy Lee; Avo Artinyan; Brian Mailey; Alessio Pigazzi; Joshua Ellenhorn; Joseph Kim
Journal:  J Gastrointest Surg       Date:  2010-05-18       Impact factor: 3.452

4.  Treatment with somatostatin analogs and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas.

Authors:  J C Maiza; D Vezzosi; S Grunenwald; P Otal; R Guimbaud; A Bennet; P Caron
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

5.  Rapidly progressing malignant insulinoma presented with multiple liver metastases: a case report.

Authors:  Askin Erdogan; Erdogan Askin; Fatih Kose; Kose Fatih; Hampar Akkaya; Akkaya Hampar; Neslihan Bascil Tutuncu; Neslihan Bascil Tutuncu; Ozgur Ozyilkan; Ozyilkan Ozgur
Journal:  J Gastrointest Cancer       Date:  2010-12

6.  ¹H NMR based serum metabolic profiles associated with pathological progression of pancreatic islet β cell tumor in Rip1-Tag2 mice.

Authors:  Yongxia Yang; Ying Liu; Lingyun Zheng; Qianqian Zhang; Quliang Gu; Linlin Wang; Lijing Wang
Journal:  Int J Biol Sci       Date:  2015-04-05       Impact factor: 6.580

7.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.

Authors:  Robert T Jensen; Guillaume Cadiot; Maria L Brandi; Wouter W de Herder; Gregory Kaltsas; Paul Komminoth; Jean-Yves Scoazec; Ramon Salazar; Alain Sauvanet; Reza Kianmanesh
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

Review 8.  Multimodal Treatment of Vasoactive Intestinal Polypeptide-producing Pancreatic Neuroendocrine Tumors with Liver Metastases.

Authors:  Mari Iwasaki; Kouhei Tsuchida; Hidehito Jinnai; Toshinori Komatsubara; Takahiro Arisaka; Misako Tsunemi; Masakazu Nakano; Makoto Iijima; Hideyuki Hiraishi
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

Review 9.  Primary jejunal gastrinoma: a case report and review of the literature.

Authors:  Kevin A Wang; Yenn-Hwei Chou; Shu-Han Huang; Tong-Jong Chen
Journal:  World J Surg Oncol       Date:  2015-11-06       Impact factor: 2.754

10.  The problems of radiofrequency ablation as an approach for advanced unresectable ductal pancreatic carcinoma.

Authors:  Raffaele Pezzilli; Claudio Ricci; Carla Serra; Riccardo Casadei; Francesco Monari; Marielda D'Ambra; Roberto Corinaldesi; Francesco Minni
Journal:  Cancers (Basel)       Date:  2010-07-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.